INmune Bio Inc. INMB Archives - Page 3 of 4

WednesdayJul 17, 2019 11:10 am

TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimer’s Development, Report Suggests

Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are working to further the research and develop safe and effective drugs based on disrupting this mechanism INmune Bio has received a $1 million grant from the Alzheimer’s Association to bring its lead drug candidate, XPro1595, to the clinical testing stage Could tumor necrosis factor-alpha (TNF-α) inhibition be the next big thing in the world of Alzheimer’s disease (AD) treatment? A detailed Washington Post report focuses…

TuesdayJul 16, 2019 1:10 pm

Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595

Companies like INmune Bio are advancing the development of innovative treatment methods INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s The global market for Alzheimer’s disease (AD) treatments is forecast to double in value by 2023, reaching $4.9 billion, according to GlobalData research (http://ibn.fm/8ZqMy). The growth rate has been estimated at 10.5 percent for the forecast period. The increasing prevalence of…

WednesdayJul 03, 2019 11:00 am

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maxim Group’s Conference on Alzheimer’s Disease

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. According to the update, Tesi’s presentation addressed how INmune Bio’s XPro1595 drug candidate targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. “I was delighted to showcase INmune Bio’s development program with XPro1595 in Alzheimer’s disease,” Tesi said in the news release. “We believe…

ThursdayJun 27, 2019 3:28 pm

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) at the Forefront of Modernizing Immunology

Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop novel immunotherapies that reprogram patients’ innate immune systems to enable them to fight cancer and Alzheimer’s disease. A recent article further discussing the company reads, “Innate is an immediate, nonspecific, initial response that serves as a first line of defense against infection and cancer. Most drug-development programs concentrate on the adaptive immune response and ignore innate immunity. INmune Bio harnesses the innate immune system with a targeted biomarker approach. . . . The company’s INKmune drug is a biologic therapy. INKmune primes NK cells to eliminate…

ThursdayJun 20, 2019 2:12 pm

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treat Cancer, Alzheimer’s Disease

INmune Bio (NASDAQ: INMB), a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease, is currently developing drug candidates INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease. An article further discussing the company reads, “XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer’s disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction — the cause of dementia in Alzheimer’s. A phase I…

TuesdayJun 11, 2019 12:27 pm

QualityStocksNewsBreaks – Why INmune Bio Inc. (NASDAQ: INMB) Is ‘One to Watch’

INmune Bio (NASDAQ: INMB) is a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease. An article further discussing the company reads, “Drug candidates INKmune and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach to promote the body’s innate immune response to treat unsolved problems in medicine. . . . INmune Bio is the first biotechnology company to close an initial public offering (“IPO”) in 2019 and commence trading on The Nasdaq Capital…

TuesdayJun 11, 2019 10:55 am

INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems

INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease INmune Bio’s drug candidates include INKmune, INB03 and XPro1595 INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company headquartered in La Jolla, California. The company is hoping to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets…

WednesdayJun 05, 2019 9:28 am

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019. According to the update, “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (“AD”) patients,” is the title of the poster and talk in which Barnum will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease. “XPro1595 has been represented…

MondayJun 03, 2019 11:56 am

INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitational

A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease INMB received a $1 million grant from the Alzheimer’s Association to fund XPro1595 research and upcoming clinical trials in patients with Alzheimer’s disease INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements…

ThursdayMay 30, 2019 10:01 am

INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cancer

INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease The company was awarded a $1 million “Part the Cloud” grant from the Alzheimer’s Association to advance XPro1595 research INmune recently entered a common stock purchase agreement for up to $20 million with Lincoln Park Capital INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to…

Site Search

Company Search

Tag: INmune Bio Inc. INMB